ENTITY

Symbio Pharmaceuticals (4582 JP)

34
Analysis
Health CareJapan
Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.
more
21 Feb 2020 22:30Issuer-paid

SymBio Pharmaceuticals - Supply issues continue

SymBio reported sales of $25.8m (¥2.838bn) for 2019 and an operating loss of $39.1 (¥4.301bn). Sales were down from 2018 due to the previously...

Share
21 Feb 2020 16:46Issuer-paid

SymBio Pharmaceuticals - Supply issues continue

SymBio reported sales of ¥2.838bn for 2019 and an operating loss of ¥4.301bn. Sales were down from 2018 due to the previously announced quality...

Share
05 Dec 2019 23:38Issuer-paid

SymBio Pharmaceuticals - Treakisym has positive DLBCL results

On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients...

Share
05 Dec 2019 17:02Issuer-paid

SymBio Pharmaceuticals - Treakisym has positive DLBCL results

On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients...

Share
07 Dec 2018 20:08Issuer-paid

SymBio Pharmaceuticals - Preparing to establish own sales organisation

SymBio announced in October that it has begun preparations to establish its own sales organisation to market Treakisym and other anticancer drugs...

Share
x